Treatment with thiazolidine derivatives, one type of anti-diabetic drugs, ameliorates insulin resistance and increases serum adiponectin level in T2DM patients with hypoadiponectinemia [5]. This evidence concerns the gene ADIPOQ and adiponectin deficiency.